You are here

Contact:
Jon Dobson
202-434-7272
Jdobson@advamed.org
May 13, 2015

AdvaMed Statement On Chairman’s Mark For 21st Century Cures

WASHINGTON, D.C. – JC Scott, senior executive vice president, government affairs, of the Advanced Medical Technology Association (AdvaMed), issued the following statement today on the release of the chairman’s mark for the House Energy and Commerce Committee’s 21st Century Cures initiative: 

“AdvaMed commends Chairman Fred Upton (R-Mich.) and Representatives Diana DeGette (D-Colo.), Frank Pallone (D-N.J.), Joe Pitts (R-Pa.), and Gene Green (D-Texas) for their leadership on exploring ways to accelerate the discovery, development and delivery of new treatments and cures in the U.S. This is an issue that affects every American family, and the strong bipartisan support for moving forward is heartening.

“While we are still reviewing the details of the chairman’s mark, we are pleased that it continues to include a number of proposals to improve the innovation ecosystem that supports the development of life-saving, life-enhancing medical technology.

“The draft includes key improvements to FDA’s premarket program for medical devices – most significantly the establishment of an expedited pathway for breakthrough, innovative technologies – which will increase the efficiency, predictability and transparency of the agency’s review process and improve patient access to the best in medical progress.

“We also appreciate the committee’s continued support of significant regulatory reforms and increased NIH funding which will help strengthen our R&D infrastructure.

“21st Century Cures is an important initiative for strengthening the innovation ecosystem in the U.S. We look forward to working with members of the committee and their counterparts in the Senate, the administration and other stakeholders to advance this worthy initiative.

“As the process moves forward, we also look forward to working with Energy & Commerce, along with other committees of jurisdiction, to address the full range of weak points in the innovation ecosystem, including the Medicare coverage delays and payment challenges that are discouraging investment in new medical innovations.”

# # #

AdvaMed member companies produce the medical devices, diagnostic products and health information systems that are transforming health care through earlier disease detection, less invasive procedures and more effective treatments.